DCGI Orders States to Enforce Global Pharma Standards by January 2025
In a major push to enhance drug safety, the Drugs Controller General of India (DCGI) has instructed state drug regulators to implement WHO-GMP standards by January 2025 and conduct rigorous inspections to ensure compliance. The move follows global concerns over substandard Indian-made medicines, including the Gambia and Uzbekistan cough syrup incidents.
Key Directives from the DCGI
The DCGI has issued strict guidelines to state drug controllers, including:
✔ Mandatory WHO-GMP Compliance – All pharma units must upgrade to WHO and Schedule M standards by January 2025.
✔ Surprise Inspections – States must inspect high-risk manufacturers, especially those exporting drugs.
✔ Penalties for Non-Compliance – Facilities failing to meet standards risk license suspension or cancellation.
✔ Stricter Quality Control – Manufacturers must improve documentation, staff training, and testing protocols.
Why This Directive is Crucial
India, the world’s largest supplier of generic drugs, faces growing scrutiny over drug quality. The DCGI’s order aims to:
🔹 Restore global trust in Indian pharmaceuticals.
🔹 Reduce substandard & counterfeit drugs in domestic and export markets.
🔹 Align India’s regulations with international benchmarks.
Dr. Rajeev Raghuvanshi, DCGI, emphasized: “This is about ensuring every Indian-made drug, whether for local or global use, meets the highest safety standards.”
Challenges in Implementation
While the move is progressive, hurdles remain:
💰 High Upgrade Costs – Small manufacturers may struggle with WHO-GMP compliance.
⚖️ Uneven State Enforcement – Regulatory capacity varies across states.
⏳ Tight Deadline – Only months remain for pharma units to meet requirements.
Industry & Expert Responses
- Pharma Associations seek financial aid for small-scale units.
- Health Advocates applaud stricter enforcement to protect patients.
Next Steps
The DCGI plans a centralized compliance tracking system, potentially positioning India as a global leader in drug safety.
Conclusion
India’s push for global pharma standards could transform its industry—but success depends on government support, industry cooperation, and strict enforcement.
Stay updated with the latest pharma regulatory news on NextMinuteNews.
